DLB vs IMAX: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

DLB is the larger of the two ($5.29B market cap): the incumbent the market prices for continued execution (12.44x forward earnings, beta 0.78). IMAX is the smaller challenger ($2.58B), actually pricier on forward earnings (20.59x): more room to run, but more to prove. If you believe IMAX earns its premium (20.59x forward earnings, so the market expects more from it), IMAX fits. If you believe in paying less for profit, DLB fits at 12.44x.

DLB vs IMAX: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricDLBIMAXWhat it tells you
Market cap$5.29B$2.58BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E12.4420.59Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E20.9019.83Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta0.780.51Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range38% of range56% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book2.015.26How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: DLB is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how DLB and IMAX affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. DLB and IMAX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined DLB and IMAX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Dolby Laboratories (DLB) do?

Dolby Laboratories licenses audio and imaging technologies to device makers, content creators, and distributors, earning royalties each time its formats are embedded in hardware or content. Its flagship brands (Dolby Atmos for immersive audio and Dolby Vision for HDR imaging) sit inside televisions, smartphones, PCs, set-top boxes, sound systems, streaming platforms, cinemas, and increasingly automotive infotainment. The model is asset-light: Dolby invests heavily in R&D and standardization, then monetizes the resulting patents and trademarks at very high gross margins once a format reaches critical mass.

Full DLB guide

What does IMAX Corporation (IMAX) do?

IMAX Corporation designs and markets premium large-format cinema systems and licenses proprietary technology that lets studios remaster films into the IMAX format. Rather than owning most theaters itself, IMAX runs an asset-light model: it sells or leases its projection and sound systems to exhibitor partners, then earns ongoing revenue tied to ticket sales through revenue-share and joint-venture arrangements. Its two reporting segments are Technology Products and Services (the systems, maintenance, and network operations) and Content Solutions (film remastering, distribution, and the growing slate of local-language titles). By 2025 the IMAX network spanned more than 1,700 theaters globally, larger than rival premium formats.

Full IMAX guide

DLB vs IMAX: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • DLB drivers: Atmos and Vision penetration; Automotive as a new surface.
  • IMAX drivers: Record box office and premium share; Local-language content expansion.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Dolby's revenue is concentrated in patent and technology licensing, so expiring patents and the need to keep introducing successful new formats are structural risks to long-term royalty streams. For IMAX, iMAX's results depend heavily on the theatrical film release calendar, which it does not control, so a weak slate of major titles in any period can pressure box office and revenue.

DLB or IMAX: which should you pick?

If the story you believe is DLB's (Atmos and Vision penetration), DLB is the more direct way to own it; if it is IMAX's (Record box office and premium share), IMAX is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the DLB and IMAX guides.

DLB vs IMAX: the full fundamentals

DLB. Dolby trades at about 21 times trailing GAAP earnings, a multiple that falls to about 12.5 times forward non-GAAP estimates (consensus near $4.35 per share for fiscal 2027 and $4.54 for fiscal 2028). The valuation embeds a steady, high-margin licensing franchise with about $623 million of cash against about $46 million of debt and trailing free cash flow of roughly $314 million, not a rapid grower. The next report, for the December 2026 quarter, is expected in late January 2027, with consensus near $0.50 per share on about $295 million of revenue after the low guide.

IMAX. The record third quarter collapsed the gap between trailing and forward P/E that defined the debate in October (about 72 versus 24): both now sit near 20 to 21 times, because trailing earnings caught up while 2027 estimates point lower. The shares are up about 30% year to date and 32% over a year but about 12% below their mid-October level, and the 12 analysts tracked by Yahoo Finance carry a buy consensus with a mean target of $60, about 28% above the 20 November close.

Headline figures (approximate, November 2026): DLB shows revenue (fy2026) ~$1.42B, up ~5%; fiscal Q4 2026 ~$374M, up ~22% year over year, net income (fy2026) ~$258M (FY2025 ~$255M), margins (ttm) Gross ~87%, operating ~22.5%, net ~18.1%, fiscal q4 2026 eps $1.25 non-GAAP vs ~$1.19 consensus; FY2026 non-GAAP $4.36; IMAX shows revenue (ttm to september 2026) ~$484 million; Q3 2026 revenue ~$174.6 million, up ~64% year over year and ~7% above consensus, margins (ttm) Gross ~64%, operating ~31%, net ~28%; Q3 2026 adjusted EBITDA margin ~66%, net income / eps (ttm) ~$134 million net income; EPS ~$2.36 trailing; Q3 2026 adjusted EPS $2.21 vs $1.02 expected, p/e ~20x trailing, ~21x forward.

The bottom line: DLB vs IMAX

DLB and IMAX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined DLB and IMAX exposure against your real portfolio. It is not an investment adviser.

Wondering how DLB or IMAX fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Dolby Laboratories

Ask Walnut's AI anything about DLB and see how it fits what you own.

FAQ

What is the difference between DLB and IMAX?

+

Dolby Laboratories licenses audio and imaging technologies to device makers, content creators, and distributors, earning royalties each time its formats are embedded in hardware or content. IMAX Corporation designs and markets premium large-format cinema systems and licenses proprietary technology that lets studios remaster films into the IMAX format. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is DLB or IMAX the better stock?

+

Neither is universally better. DLB is the larger incumbent; IMAX is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, DLB or IMAX?

+

On forward P/E (as of November 2026), DLB trades at 12.44x and IMAX at 20.59x, so DLB is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both DLB and IMAX?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of DLB vs IMAX?

+

DLB: Dolby's revenue is concentrated in patent and technology licensing, so expiring patents and the need to keep introducing successful new formats are structural risks to long-term royalty streams. Results are exposed to consumer-electronics cyclicality and are lumpy because of periodic licensing true-ups and catch-up payments, which can swing quarterly comparisons meaningfully. A slowdown in TV, smartphone, or PC unit shipments would directly pressure royalties, and license renewals with major device makers can reset economics. Competition from Xperi/DTS, Sony, and other audio and imaging IP holders, plus the risk that a customer favors royalty-free or in-house alternatives, could erode share over time. Growth is modest, so multiple compression is a risk if the market expects more than mid-single-digit expansion. The June 2026 quarter, when revenue fell about 3% year over year and GAAP net income dropped to about $29 million, and the fiscal Q1 2027 guide of $285-305 million of revenue against a consensus near $359 million, are recent examples of how uneven individual quarters can be. With fiscal 2027 revenue guided roughly flat at about $1.42 billion, the growth case rests on years beyond the next one. IMAX: IMAX's results depend heavily on the theatrical film release calendar, which it does not control, so a weak slate of major titles in any period can pressure box office and revenue. Greater China is a swing market: IMAX box office there plunged roughly 62% in the first quarter of 2026 against a very strong prior-year period, showing how concentrated and volatile that geography can be. Competition from Dolby Cinema, Cinemark XD, Regal RPX, ScreenX, 4DX, and exhibitors' own premium-format brands is intensifying, and some operators resent the revenue cut IMAX takes. Longer term, the shift toward streaming and shorter theatrical windows could erode moviegoing. The nearer risk is the comparison: consensus has 2026 EPS of about $3.41 falling to about $2.27 in 2027 on revenue of about $501 million, barely above 2026's expected $489 million, and the December 2026 quarter is expected to show EPS of about $0.57 on revenue roughly 1% lower than a year earlier. A year without an Odyssey-sized release makes those comparisons harder, and the stock fell about 12% in the month to 20 November 2026 despite the third quarter beat.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell DLB or IMAX; figures are approximate and dated (as of November 2026). Verify current data before investing.